Literature DB >> 14616780

Contrasting activity of cytosin-guanosin dinucleotide oligonucleotides in mice with experimental colitis.

F Obermeier1, N Dunger, U G Strauch, N Grunwald, H Herfarth, J Schölmerich, W Falk.   

Abstract

Intestinal inflammation in inflammatory bowel disease (IBD) and experimental models of colitis is characterized by a dysregulated intestinal immune response with elevated levels of Th1 cytokines. The luminal flora has been implicated as a major factor contributing to the initiation and perpetuation of inflammation in experimental colitis by mechanisms not known. Bacterial DNA contains unmethylated cytosin-guanosin dinucleotides (CpG) which strongly activate Th1-mediated immune responses. To test whether these CpG-motifs modulate intestinal inflammation we treated mice with dextran sulphate sodium (DSS)-induced colitis with CpG-containing oligodeoxynucleotides (CpG-ODN). CpG-ODN given after the onset of DSS colitis aggravated the disease, as indicated by a significantly increased loss of body weight and a 30% increase of the histological score. Further, we found a severe increase of proinflammatory cytokines (interleukin (IL)-6: 40-fold; interferon (IFN)-gamma: 11-fold). In a pretreatment setting CpG-ODN reduced weight loss significantly and reduced intestinal inflammation by 45%. Colonic IFN-gamma and IL-6 mRNA levels were reduced by 75%, and IL-10 was elevated by 400% compared to controls. The prophylactic CpG-effect was not imitated by IL-12 because IL-12 pretreatment was not protective. In time-course experiments, CpG-ODN pretreatment over 5 days resulted in a tolerance effect concerning its IFN-gamma-inducing quality, and during the following days of colitis induction IL-10 secretion from mesenterial lymph node cells was elevated compared to controls. Therefore, the prophylactic effect of CpG-ODN might be explained by its tolerizing effect and/or the increased ability for IL-10 production during the consecutive intestinal inflammation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14616780      PMCID: PMC1808852          DOI: 10.1046/j.1365-2249.2003.02288.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  40 in total

Review 1.  CpG motifs in bacterial DNA and their immune effects.

Authors:  Arthur M Krieg
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

Review 2.  Recent developments in adjuvants for vaccines against infectious diseases.

Authors:  D T O'Hagan; M L MacKichan; M Singh
Journal:  Biomol Eng       Date:  2001-10-15

3.  Induction of tolerance to lipopolysaccharide and mycobacterial components in Chinese hamster ovary/CD14 cells is not affected by overexpression of Toll-like receptors 2 or 4.

Authors:  A E Medvedev; P Henneke; A Schromm; E Lien; R Ingalls; M J Fenton; D T Golenbock; S N Vogel
Journal:  J Immunol       Date:  2001-08-15       Impact factor: 5.422

Review 4.  Now I know my CpGs.

Authors:  A M Krieg
Journal:  Trends Microbiol       Date:  2001-06       Impact factor: 17.079

5.  Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis.

Authors:  Daniel Rachmilewitz; Fanny Karmeli; Kenji Takabayashi; Tomoko Hayashi; Leonor Leider-Trejo; Jongdae Lee; Lorenzo M Leoni; Eyal Raz
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

6.  Interleukin-1beta induces in vivo tolerance to lipopolysaccharide in mice.

Authors:  F Alves-Rosa; M Vulcano; M Beigier-Bompadre; G Fernández; M Palermo; M A Isturiz
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

7.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease.

Authors:  Y Ogura; D K Bonen; N Inohara; D L Nicolae; F F Chen; R Ramos; H Britton; T Moran; R Karaliuskas; R H Duerr; J P Achkar; S R Brant; T M Bayless; B S Kirschner; S B Hanauer; G Nuñez; J H Cho
Journal:  Nature       Date:  2001-05-31       Impact factor: 49.962

8.  CpG DNA induces self and cross-hyporesponsiveness of RAW264.7 cells in response to CpG DNA and lipopolysaccharide: alterations in IL-1 receptor-associated kinase expression.

Authors:  Seon-Ju Yeo; Jae-Geun Yoon; Soon-Cheol Hong; Ae-Kyung Yi
Journal:  J Immunol       Date:  2003-01-15       Impact factor: 5.422

9.  CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice.

Authors:  Florian Obermeier; Nadja Dunger; Ludwig Deml; Hans Herfarth; Jürgen Schölmerich; Werner Falk
Journal:  Eur J Immunol       Date:  2002-07       Impact factor: 5.532

10.  Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide.

Authors:  Iris Caramalho; Thiago Lopes-Carvalho; Dominique Ostler; Santiago Zelenay; Matthias Haury; Jocelyne Demengeot
Journal:  J Exp Med       Date:  2003-02-17       Impact factor: 14.307

View more
  45 in total

1.  Coordination between TLR9 signaling in macrophages and CD3 signaling in T cells induces robust expression of IL-30.

Authors:  Denada Dibra; Jeffry J Cutrera; Shulin Li
Journal:  J Immunol       Date:  2012-03-09       Impact factor: 5.422

2.  Toll-like receptor-7 ligand Imiquimod induces type I interferon and antimicrobial peptides to ameliorate dextran sodium sulfate-induced acute colitis.

Authors:  Satheesh K Sainathan; Kumar S Bishnupuri; Konrad Aden; Qizhi Luo; Courtney W Houchen; Shrikant Anant; Brian K Dieckgraefe
Journal:  Inflamm Bowel Dis       Date:  2011-09-26       Impact factor: 5.325

3.  Illuminating the role of type I IFNs in colitis.

Authors:  Stefan Wirtz; Markus F Neurath
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

Review 4.  NOD2 regulation of Toll-like receptor responses and the pathogenesis of Crohn's disease.

Authors:  T Watanabe; A Kitani; W Strober
Journal:  Gut       Date:  2005-11       Impact factor: 23.059

Review 5.  Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2.

Authors:  E Cario
Journal:  Gut       Date:  2005-04-19       Impact factor: 23.059

6.  Probiotics in IBD: mucosal and systemic routes of administration may promote similar effects.

Authors:  B Foligné; C Grangette; B Pot
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

Review 7.  Immunopathogenesis of inflammatory bowel disease.

Authors:  David Q Shih; Stephan R Targan
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

Review 8.  Therapeutic implications of manipulating and mining the microbiota.

Authors:  Fergus Shanahan
Journal:  J Physiol       Date:  2009-06-08       Impact factor: 5.182

9.  Toll-like receptors mediated signalings: friends or enemies?

Authors:  Yan Zhang
Journal:  Dig Dis Sci       Date:  2013-10       Impact factor: 3.199

Review 10.  Toll-like receptors in inflammatory bowel disease-stepping into uncharted territory.

Authors:  Avi Levin; Oren Shibolet
Journal:  World J Gastroenterol       Date:  2008-09-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.